Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin vs Cisplatin with Pemetrexed in Advanced Lung Adenocarcinoma
NCT02607592Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2015
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nedaplatin in lung adenocarcinoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
nedaplatin
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02607592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607592.